



Co-Founder and CEO of InPress Technologies Makes Forbes 2015 “30 Under 30” List in Healthcare

25-Year-Old Jessie Becker Developing Non-Invasive Device to Treat Postpartum Hemorrhage

MOUNTAIN VIEW, Calif. – January 9, 2015 – Jessie Becker, co-founder and CEO of [InPress Technologies](#) (InPress), is among the select bright stars voted onto the [2015 Forbes “30 Under 30” list in the healthcare category](#). The 25-year-old innovator, whose medical technology company is committed to developing a device that will eradicate maternal death caused by postpartum hemorrhage (PPH), is also among just a handful of game-changing women in this year’s healthcare class. Becker’s start-up is noted for raising \$1.5 million in seed money, including from legendary California inventor and investor Thomas Fogarty.

“The InPress device aims to quickly and effectively stop postpartum hemorrhage, the leading cause of maternal death globally,” said Becker. “To be named one of Forbes magazine’s top 30 young disruptors in healthcare today is both an honor and a tremendous validation of our simple device’s potential to save the lives of women around the world. It is also a testament to the exceptional team behind its development.”

Forbes’ complete 2015 “30 Under 30” list features 600 young entrepreneurs in 20 categories, each vetted by a blue-ribbon panel of experts in their respective fields. This year’s judges for the healthcare sector included: Jonathan Rothberg, chief strategy officer of start-up accelerator 4Catalyzer; Bob Kocher, partner at Venrock, a pioneering venture capital firm with a primary focus on technology and healthcare; and, Christi Shaw, U.S. country head and president at Swiss multinational pharmaceutical company Novartis Corporation.

Making it onto the Forbes “30 Under 30” roster comes on the heels of a watershed year for InPress. In 2014, the company began enrolling patients in its first clinical trial in Jakarta, Indonesia, in addition to achieving internationally-recognized ISO 13485 certification. Early results of the company’s 10-patient clinical trial, which has enrolled nine patients and will conclude sometime this quarter, have been 100 percent successful.

As opposed to only treating the symptoms of PPH, which is typically done with pharmaceuticals, hysterectomy or other invasive surgical procedures, the InPress device is

designed to stop the leading cause of postpartum bleeding by stimulating uterine contraction. Inserted into the uterus upon childbirth, it has the potential to dramatically reduce the cost of healthcare during childbirth and substantially reduce the risk of loss of life.

About InPress Technologies

Located in Mountain View, Calif., InPress Technologies is committed to developing a medical device that will eradicate maternal death caused by postpartum hemorrhage (PPH). With its simple, non-invasive InPress device, the company aims to improve the lives of women around the world. More information on InPress Technologies is available at www.inpresstechnologies.com.

###

MEDIA CONTACT:

Diana Soltesz

Nobles Global Communications

818-592-6747

diana@noblesgc.com